There have been more than 30 initial public offerings of biotechnology companies so far this year, and there’s a line around the block of promising new entrants looking to debut on the public markets.
But don’t call it a bubble. Those in the know are calling it a boom, and saying the good times are likely to continue for biotech, even in the face of clinical setbacks and other bumps in the road.
Image Courtesy of lemonade / FreeDigitalPhotos.net
